Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.

Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.

Abstract: A feedback control mechanism for a fermentation of yeast cells to make recombinant proteins uses a respiratory quotient measurement which adjusts the levels of oxygenation and/or fermentable sugar feed. The feedback control mechanism permits well controlled cultures that produce good amounts of product while avoiding toxic accumulation of ethanol. Additionally, recombinant proteins so produced have excellent qualitative properties, such as excellent homogeneity and proper inter-subunit assembly.

Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.

Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.

Abstract: The present invention provides a method for screening for an autophagy activator or inhibitor comprising the steps of: (a) making a test material to be analyzed come into contact with cells containing Beclin 1 protein; and (b) analyzing the degree of phosphorylation at the 30th serine amino acid residue of the Beclin 1 protein. The test material is determined to be an autophagy activator when the phosphorylation of the Beclin 1 protein is up-regulated, and the test material is determined to be an autophagy inhibitor when the phosphorylation of the Beclin 1 protein is down-regulated. The present invention first establishes, by ULK1, the mechanism of phosphorylation at the 30th serine amino acid residue of Beclin 1.

Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.

Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.

Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.

Abstract: Disclosed are binding proteins, or fragments thereof, that specifically binds to a cancer-specific glycosylation variant of a protein and to a second epitope on the same protein, to a different protein presented on the same cell, or to a different protein presented on a different cell, such as an encoded polypeptide binding to both a cancer cell and an activated T cell. Also disclosed are polynucleotides encoding such binding proteins, including polynucleotides comprising codon-optimized coding regions and polynucleotides comprising coding regions that are not codon-optimized for expression in a particular host cell. Also disclosed are methods of making the encoded polypeptide and methods of using the polypeptide to treat, prevent or ameliorate the symptom of a disease such as cancer.

Abstract: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognizing said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to methods of producing said antibodies, methods of inhibiting MASP-2 activity as well as to pharmaceutical compositions comprising the MASP-2 antibodies.

Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.

Abstract: The present disclosure is generally directed to biopolymers having coiled nanostructures, methods of making those biopolymers, and applications involving those biopolymers. Biopolymers having coiled nanostructures may be produced through a biophysical process by which the shape of a biopolymer macromolecular chain is altered. Biopolymers having coiled nanostructures may then be cross-linked to prepare biopolymeric networks. The biopolymeric networks may be configured to incorporate solid particles, in which they serve to hold the solid particles together against external stresses, solvents, and the like. For this reason, the biopolymers having coiled nanostructures are useful in a variety of applications, including in an improved process for forming iron ore pellets.

Abstract: The invention relates to a modified diene elastomer comprising predominantly the entity functionalized in the middle of the chain by a silanol group, the silicon atom of which bonds the two pieces of the chain, the chain ends of the modified diene elastomer being functionalized to at least 70 mol %, with respect to the number of moles of chain end, by an amine functional group.

Abstract: Provided is a method of forming a polymer, comprising (a) providing a reaction mixture comprising (i) one or more vinyl monomers, (ii) one or more pH-sensitive inhibition systems, (iii) one or more initiators, and (iv) water; (b) establishing conditions in said reaction mixture such that a free radical polymerization of said vinyl monomer occurs at a location, and (c) after steps (a) and (b) and prior to completion of said free radical polymerization, changing the pH of said reaction mixture to increase the rate of generation of said free radical polymerization at the location of said free radical polymerization.

Abstract: The present disclosure provides a novel transition metal compound having excellent structural stability together with polymerization reactivity, and thereby is useful as a catalyst in preparing an olefin-based polymer, particularly, a low density olefin-based polymer, and a catalyst composition including the same.

Abstract: Catalyst systems and methods for making and using the same. A method for making a catalyst support includes forming a mixture of a support material and a fluoride donor. The mixture is added to a fluidized bed reactor. The mixture is fluidized to form a fluidized bed with a height to diameter ratio of at least about 2.3. The mixture is calcined to decompose the fluoride donor, forming a fluorinated support.

Abstract: The present invention is directed to partially fluorinated copolymers and the production thereof. More specifically, the copolymers, which are preferably produced by a solution polymerization process, preferably have at least three units, the first unit selected from 2,3,3,3-tetrafluoropropene and 1,3,3,3-tetrafluoropropene, the second unit having a polymerized monomer selected from the vinyl esters and vinyl ethers, and the third unit having a polymerized monomer derived from a hydroxyl group-containing vinyl ether. The resulting copolymer is environmentally friendly, has favorable molecular weight characteristics, and may be shipped economically in high concentration.

Abstract: An in situ method of preparing modified polyvinyl acetals is described with the aim of improving the alcohol tolerance while retaining barrier properties of the base polymer.

Abstract: Provided are a hybrid supported catalyst system and a method of preparing a polyolefin using the same. The hybrid supported catalyst system according to the present invention may be used to perform oligomerization and copolymerization of olefin monomers in a single reactor at the same time with high efficiency without a separate process of preparing alpha-olefin. Therefore, costs for preparing or purchasing comonomers which are expensive raw materials may be reduced, thereby reducing the production cost of a final product.

Abstract: The invention relates to a process for manufacturing polyethylene or an ethylene copolymer, comprising a step of radical polymerization or copolymerization of ethylene in the presence: of a first peroxide polymerization initiator chosen from the diperketal peroxide compounds of formula: in which the R1, R2, R3, R6, R7 and R8 groups consist of substituted or unsubstituted, linear, branched or cyclic C1-C10 alkyl groups, of a second initiator, other than said first initiator, also consisting of a diperketal peroxide of formula (I).

Abstract: Provided herein are VLDPE polymer compositions suitable for use in the manufacture of flexible films or sheets. In one embodiment, the copolymer comprises a polyethylene VLDPE resin with Mz/Mw of greater than 2, CDBI50 of greater than 55 and a single melting peak in DSC measurement. The polymer compositions disclosed herein may be suitable for use in the manufacture of films with improved balance of film toughness, processability and sealability in monolayer and multi-layer film structures.

Abstract: Catalyst systems and methods for making and using the same. A method of polymerizing olefins to produce a polyolefin polymer with a multimodal composition distribution, includes contacting ethylene and a comonomer with a catalyst system. The catalyst system includes a first catalyst compound and a second catalyst compound that are co-supported to form a commonly supported catalyst system. The first catalyst compound includes a compound with the general formula (C5HaR1b)(C5HcR2d)HfX2. The second catalyst compound includes at least one of the following general formulas: In both catalyst systems, the R groups can be independently selected from any number of substituents, including, for example, H, a hydrocarbyl group, a substituted hydrocarbyl group, or a heteroatom group, among others.

Abstract: The present disclosure provides high density polyethylene resins having good low temperature impact resistance. The resins are suitable for use in rotomolding application for large parts. The resin is a bi- or trimodal resin produced using solution phase polymerization in the presence of a single site catalyst.

Abstract: A polysulfide material having reactive vinyl end groups and a method of making a vinyl end-capped polysulfide material are described. The vinyl end-capped polysulfide material has potential applications as a sealant, an adhesive, a coating, a caulking, or the like. In a specific example, the polysulfide material may be used as a precursor material for a sealant resin in the manufacturing of an integral fuel tank of an aircraft. An example method for making polysulfide materials includes contacting a vinyl-functionalized aryl halide and/or a vinyl-functionalized heteroaryl halide with dithiols and/or trithiols in the presence of an organic solvent.

Abstract: The invention relates to a method for preparation of a polymer from monomers comprising polyvinylidene fluoride, trifluoroethylene and a third monomer, the method successively comprising: injection of all the monomers to react into a reactor; initiation of a polymerization of the monomers; a continuation step (a) of the polymerization of the monomers, during which a drop in pressure in the reactor is compensated.

Abstract: The present invention aims to provide an ionomer that can exhibit high oxygen permeability, especially under both low- and high-humidified conditions, and high power generation durability. The high oxygen permeable ionomer includes a specific repeating unit A and repeating unit B and has an equivalent weight of 250 to 930 and a glass transition temperature of 100° C. to 130° C.

Abstract: Provided are a curable composition having excellent releasability and ink jet discharge accuracy, a pattern forming method, a pattern, and a method for manufacturing a device. The curable composition includes a polymerizable compound and a photopolymerization initiator, in which neopentyl glycol diacrylate accounts for 10% by mass or more of the polymerizable compound, and the total content of a compound represented by the following Formula (I) and a compound represented by the following Formula (II) is 5% by mass or less with respect to the content of neopentyl glycol diacrylate.

Abstract: An object of the present invention is to provide an active energy ray-curable composition capable of forming a cured product excellent in damage restoration, adhesion to a plastic base, and transparency after curing. An active energy ray-curable composition for optical components of the present invention essentially includes: a monomer (A) having 2 or more radical-polymerizable reactive groups (x1), a homopolymer of the monomer (A) having a glass transition temperature of higher than 200° C.; a monomer (C) having 2 or more radical-polymerizable reactive groups (x2), a homopolymer of the monomer (C) having a glass transition temperature of lower than ?15° C.; and a photopolymerization initiator (E).

Abstract: The present invention relates to radiation curable compositions (A) comprising—(a) at least one photoinitiator compound of formula (I) wherein Q is the residue of a hydroxy compound having 1 to 6 hydroxyl groups, and wherein x is a number that is at least 1 but no greater than the number of hydroxyl groups originally present in said hydroxy compound;—(b) at least one ethylenically unsaturated compound selected from monomers (b1) and/or from oligomers (b2); and—(c) optionally, at least one co-synergist which preferably is an amino co-synergist. The present invention further relates to photoinitiator compounds(a) and their preparation.

Abstract: Provided are: a graft copolymer which can be safely and stably produced with simple operation, while maintaining the characteristics of an amine, and which is lower in the introduction cost than conventional graft copolymers; and a method for producing the graft copolymer. A polyamine graft polymer that is obtained by polymerizing a polyamine derivative, which is obtained by reacting a polymer compound (a) having at least one amino group with a compound (b) having at least one epoxy group, with an ethylenically unsaturated monomer (c). A method for producing a polyamine graft polymer, which comprises a step for adding, for polymerization, an ethylenically unsaturated monomer (c) and a radical polymerization initiator to a polyamine derivative, which is obtained by reacting a polymer compound (a) having at least one amino group with a compound (b) having at least one epoxy group, in a polar solvent.

Abstract: The present invention relates to a process for the production of styrene graft copolymers comprising addition and graft copolymerization of styrene monomers A1 and vinyl cyanide monomers A2 to a graft base B where the ratio by mass of A1 to A2 in the monomer feed at the end of the monomer feed time is lower than the ration by mass integrated over the entire monomer feed time. The present invention further relates to a graft copolymer obtainable by a process according to the invention, a molding composition comprising such a graft copolymer, and a molding obtained from such a molding composition.

Abstract: A method for producing functionalized thermoplastic elastomers on the basis of grafting substrates, selected from olefine-block copolymers of composition 80 to 98 mass-% ethylene-/2 to 20 mass-% C3- to C12-olefine units or partially crystalline propylene/ethylene and/or C4- to C12-olefine and/or C4- to C12-diene-copolymers of composition 50 to 98 mass-% propylene-/2 to 50 mass-% C2- and/or C4- to C12-olefine and/or C4- to C12-diene units or cross-linked styrene/olefine/styrene or styrene/olefine-block copolymers, wherein, in a liquid mixing reactor per 100 mass parts of particular grafting substrate—0.1 to 15 mass parts of at least one functional monomer from the series of functional groups comprising ?,?-ethylenic unsaturated compounds or 0.1 to 15 mass parts of a monomer mixture comprising at least one of said functional monomers and—0.01 to 10 mass parts of at least one initiator forming free radicals having a 1-hour half-life temperature (THwz/1h) between 50 and 200° C.

Abstract: A polymerization process, preferably a living radical polymerisation process, is carried out in the presence of a template substance, to produce molecularly imprinted polymers (“MIPs”). It is controlled so that the products are quite small (500-106 Daltons) so that they are soluble or form colloidal suspensions. The template substances are immobilized templates, which can be re-used. Immobilized templates are also useful for purification of MIP solutions/suspensions by affinity chromatography.

Abstract: The invention provides new water soluble polymers for the use in industrial processes, where large quantities of water is handled, such as sludge dewatering and papermaking. These new polymers are water soluble cross-linked block copolymers, wherein the block copolymers are cross-linked together using a cross-linking agent. Each of the block copolymers contain two different blocks, and these blocks are formed from different monomers. The blocks are linked together with a molecular spacer derived from a bifunctional initiator used during the polymerization of the blocks. The monomers used in polymerizing the blocks are different with each other and they are selected from a group consisting of N-vinylformamide, acrylic acid, acrylamide and water-soluble derivatives thereof.

Abstract: Provided is a block copolymer with an acid group that, when used as a dispersant, can provide a dispersion composition having excellent dispersion stability, a dispersant containing the block copolymer, and a pigment dispersion composition using the dispersant. The block copolymer is an ABA block copolymer including an A block and a B block and has the feature that its acid value is 30 to 250 mgKOH/g and the B block contains a structural unit derived from a vinyl monomer with an acid group.

Abstract: This invention relates to a fine powder-coated amine comprising a solid amine having a melting point equal to or higher than 50° C. and a mean particle size equal to or smaller than 20 ?m. The fine powder-coated amine has an amount of heat in the second absorption peak measured by a differential scanning calorimeter equal to or less than 220 J/g, and the surface of the solid amine is coated with fine powder having a mean particle size equal to or smaller than 2 ?m.

Abstract: The invention relates to compositions comprising at least one first and one second component; —the first component K1 comprising at least one di(aminobenzoate) ester A1 of formula (I) with an average molecular weight of 500 g/mol to 2000 g/mol, preferably 600 g/mol to 1500 g/mol and particularly preferred between 650 g/mol and 1300 g/mol, G being a divalent group derived from poly(tetramethylene oxide) diol, and —the second component K2 comprising at least one aromatic polyisocyanate B1 with an average molecular weight of 160 g/mol to 1100 g/mol, preferably 500 g/mol to 800 g/mol.

Abstract: A method for curing an epoxy resin by adding to the epoxy resin a compound having formula (I) wherein X is a difunctional group selected from the group consisting of C2-C20 alkyl, C5-C20 cycloalkyl, C6-C10 aryl, C8-C20 aryl alkyl, C4-C20 heteroalkyl or C10-C20 aryl heteroalkyl.